WO2025210599 - LU]LU-PSMA-617
National phase entry is expected:
Publication Number
WO/2025/210599
Publication Date
09.10.2025
International Application No.
PCT/IB2025/053608
International Filing Date
04.04.2025
Title **
[English]
LU]LU-PSMA-617
[French]
LU]LU-PSMA-617
Applicants **
NOVARTIS AG
ARTIOS PHARMA LIMITED
Inventors
HINDUPUR, Sravanth Kumar
PINTO DO COUTO E SILVA, Joana
BARYS, Louise
REBER, Josefine Astrid
RESCHKE, Markus
SCHMELZLE, Tobias
CORTES-CROS, Marta
RANZANI, Marco
ROBINSON, Helen Marie Ruth
SMITH, Graeme Cameron Murray
Priority Data
63/575,373
05.04.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4696 | |
| EPO | Filing, Examination, Granting | 67038 | |
| Japan | Filing, Examination, Granting | 4162 | |
| South Korea | Filing, Examination, Granting | 6158 | |
| USA | Filing, Examination, Granting | 22590 |
Total:
104,644
Contact Us
Abstract[English]
Lu]Lu-PSMA-617 and a DNA Damage Response inhibitor (DDRi), and their use in treating cancers, such as, e.g., PSMA-expressing cancers.[French]
Lu]Lu-PSMA-617 et d'un inhibiteur de réponse aux dommages de l'ADN (DDRi), et leur utilisation dans le traitement de cancers, tels que des cancers exprimant le PSMA.